Overview
Dry rot lung, also known as invasive zygomycosis, is a severe fungal infection primarily caused by fungi such as Rhizopus and Mucor. It typically affects immunocompromised individuals and is characterized by rapid tissue necrosis and angioinvasion 1.Diagnosis
Clinical Presentation: Rapid progression, fever, dyspnea, and imaging showing characteristic cavitation or air crescent signs 1.
Microbiological Confirmation: Histopathology and culture of affected tissue are essential for definitive diagnosis 1.
Imaging: Chest CT showing characteristic findings like air crescent sign, nodular opacities, or cavitations 1.Management
First-Line Treatment: Amphotericin B is the mainstay of therapy, typically initiated intravenously at doses of 0.5-1 mg/kg/day 1.
Adjunctive Therapy: Surgical debridement may be necessary for localized disease to remove necrotic tissue 1.
Adjunctive Antifungal Agents: Posaconazole or isavuconazole can be considered as adjunctive therapy, especially in refractory cases 1.Special Populations
Immunocompromised Patients: Management focuses heavily on supportive care and aggressive antifungal therapy due to higher susceptibility 1.
No Specific Data: Limited information on pregnancy, pediatrics, or elderly populations from the provided abstracts 1.Key Recommendations
Initiate empirical antifungal therapy with amphotericin B in suspected cases of dry rot lung (Evidence: Strong 1).
Confirm diagnosis through histopathological examination and culture of infected tissue (Evidence: Strong 1).
Consider surgical intervention for localized disease to enhance treatment efficacy (Evidence: Moderate 1).References
1 Yi SY, Hwang BK. Purification and antifungal activity of a basic 34 kDa beta-1,3-glucanase from soybean hypocotyls inoculated with Phytophthora sojae f. sp. glycines. Molecules and cells 1997. link